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Abstract
Introduction. Neuroleptic malignant syndrome is rare, but
potentially fatal idiosyncratic reaction to antipsychotic medica-
tions. It is sometimes difficult to diagnose some clinical cases
as neuroleptic malignant syndrome and differentiate it from
the acute viral encephalitis. Case report. We reported a pa-
tient diagnosed with acute psychotic reaction which appeared
for the first time. The treatment started with typical antipsy-
chotic, which led to febrility. The clinical presentation of the
patient was characterised by the signs and symptoms that
might have indicated the neuroleptic malignant syndrome as
well as central nervous system viral disease. In order to make a
detailed diagnosis additional procedures were performed:
electroencephalogram, magnetic resonance imaging of the
head, lumbar puncture and a serological test of the cerebro-
spinal fluid. Considering that after the tests viral encephalitis
was ruled out and the diagnosis of neuroleptic malignant syn-
drome made, antipsychotic therapy was immediately stopped.
The patient was initially treated with symptomatic therapy and
after that with atypical antipsychotic and electroconvulsive
therapy, which led to complete recovery. Conclusion. We
present the difficulties of early diagnosis at the first episode of
acute psychotic disorder associated with acute febrile condi-
tion. Concerning the differential diagnosis it is necessary to
consider both neuroleptic malignant syndrome and viral en-
cephalitis, i.e. it is necessary to make the neuroradiological di-
agnosis and conduct cerebrospinal fluid analysis and blood
test. In neuroleptic malignant syndrome treatment a combined
use of electroconvulsive therapy and low doses of atypical an-
tipsychotic are confirmed to be successful.
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Apstrakt
Uvod. Maligni neuroleptiÿki sindrom je retka, potencijalno
fatalna, idiosinkratska reakcija na antispihotiÿnu terapiju. U
nekim kliniÿkim sluÿajevima je teško postaviti diferencijal-
nu dijagnozu izmeĀu malignog neuroleptiÿnog sindroma i
akutnog virusnog encefalitisa. Prikaz bolesnika. U ovom
radu prikazan je bolesnik kod koga je prvi put dijagnosti-
kovana akutna psihotiÿna reakcija i zapoÿeto leÿenje tipiÿ-
nim antipsihotikom, nakon ÿega je došlo do razvoja febril-
nosti. Kliniÿka slika odlikovala se znakovima i simptomi-
ma koji su mogli ukazivati i na maligni neuroleptiÿni sin-
drom i na virusno oboljenje centralnog nervnog sistema. U
cilju detaljnog dijagnostikovanja uraĀene su dodatne pro-
cedure: elektroencefalografija, magnetna rezonanca glave,
lumbalna punkcija i serološke analize likvora. S obzirom
na to da je nakon toga iskljuÿen virusni encefalitis i posta-
vljena dijagnoza malignog neuroleptiÿkog sindroma, bole-
sniku je odmah iskljuÿena antipsihotiÿna terapija. Leÿen je
prvo simptomatskom terapijom, a potom atipiÿnim antip-
sihotikom i elektrokonvulzivnom terapijom, nakon ÿega je
došlo do potpunog oporavka. Zakljuÿak. Prikazane su te-
škoýe rane dijagnoze kod prve epizode akutnog psihotiÿ-
nog poremeýaja udruženog sa akutno nastalim febrilnim
stanjem. Diferencijalnodijagnostiÿki je neophodno razmot-
riti pojavu malignog neuroleptiÿkog sindroma i virusnog
encefalitisa, odnosno potrebno je uraditi neuroradiološku
dijagnostiku, i analizu likvora i krvi. U terapiji malignog
neuroleptiÿkog sindroma potvrĀena je uspešnost kombi-
novane primene elektrokonvulzivne terapije i niskih doza
atipiÿnog antipsihotika.
Kljuÿne reÿi:
neuroleptiÿki maligni sindrom; encefalitis, virusni;
dijagnoza; dijagnoza, diferencijalna; leÿenje, ishod.
Introduction
In the psychiatric clinical practice, it is sometimes very
difficult to differentiate an organic acute psychotic reaction
from neuroleptic malignant syndrome (NMS)
 1, 2. NMS may
mask an infectious disease of the central nervous system
(CNS), while, on the other hand, CNS infection itself may be
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to the applied antipsychotic drug therapy 
3, 4. However, acute
viral encephalitis, whose clinical picture primarily includes
pronounced psychiatric phenomenology, constitutes a par-
ticular problem.
Acute viral encephalitis is a non-purulent inflamatory
disease of the brain, most commonly caused by Herpes sim-
plex viruses – type 1 (HSV-1) and type 2 (HSV-2), enterovi-
ruses, or arboviruses 
4. The onset is abrupt, acute and fol-
lowed by high temperature and headache. Disorders of con-
sciousness, personality and mood (particularly in cases of
HSV encephalitis), epileptic seizures, hemiparesis, or me-
ningeal signs and symptoms are also common occurances.
The most accurate diagnostic tool is brain biopsy, but it is
non-applicable. The other reliable parameter is the polymer-
ase chain reaction (PCR) test, with the sensitivity of 95%,
and specificity of 100% for Herpes simplex viruses. How-
ever, the other laboratory values are not considered to be a
reliable aid in the diagnosis of viral encephalitis, since the
serological test of the cerebrospinal fluid (CSF) very often
remains within the normal range.
NMS is a rare (0.02–3.22%), idiosyncratic adverse re-
action to antipsychotic drug therapy, and it is not directly
associated with antipsychotic drugs dosage 
1, 5. Such idio-
syncratic adverse reaction to antipsychotic drug therapy oc-
curs as a result of the polymorphism of dopamine receptors
and it is associated with individual genetic vulnerability to
antipsychotic medications. All antipsychotics, both typical
and atypical, might cause NMS, but high-potency antipsy-
chotic medications (haloperidol, fluphenazine) are consid-
ered a more common cause of this syndrome 
6. The etiol-
ogy of NMS has not been fully elucidated yet; it is thought
that blockade of the dopamine transmission in the ni-
grostriatum causes muscle rigidity, tremor and rhabdomy-
olysis, while the dopamine blockade in the hypothalamus
leads to the changes in thermoregulation and hyperthermia
2. Death occurs as a result of respiratory depression, car-
diovascular collapse, renal dysfunction, rhabdomyolysis,
disseminated intravascular coagulation (DIC) or pulmonary
embolism. In recent years reduction in mortality caused by
NMS has been registered, i.e. until 1970 mortality rate was
up to 76%, but since 1980 it has been gradually reducing
and now it is 10–20% 
7. Some 90% of patiens the devel-
oped NMS recover within 2 to 14 days. This period was
prolonged up to 35 days in patients receiving a depot
preparation of antipsychotic drug 
7.
In all the patients who had high temperature accompa-
nied by the change in mental status, the lumbar puncture was
indicated in order to exclude a possible CNS infection. Lum-
bar puncture and the electroencephalogram (EEG) are essen-
tial diagnostic procedures for elucidating and determining
the etiology of the altered mental status 
8, 9. EEG is an early
and sensitive indicator, so it can be used to help in the differ-
ential diagnosis of some cases. During the acute phase of the
disease focal abnormalities are often recorded on EEG. The
severity of EEG abnormalities does not usually correlate
with the severity of the disease (encephalitis), but their im-
provement predicts good prognosis 
10, 11.
Case report
A 22-year-old soldier prior to joining the Army func-
tioned adequatelly in all the spheres of his life. The patient
was treated in the regional military hospital, diagnosed with
acute psychotic reaction. As soon as his general condition
deteriorated (after 13 days), he was referred to the Clinic for
the Internal and Emergency Medicine of the Military Medi-
cal Academy (MMA), where he was kept for 3 days, and
then transferred to the MMA’s  Psychiatry Clinic for further
treatment which lasted 39 days. So, his treatment lasted two
months altogether.
Based on the heteroanamnestic data (the mother) and
the available medical documentation, it was found out that
10 days prior to his admission to the regional military hos-
pital his mood altered: he was nervous, tense, inclined to
conflict situations, physically agressive, complaining of se-
vere headaches and caugh. On admission he was psycho-
motorically agitated, with paranoid and bizarre sexual delu-
sions. The patient was initially treated with high doses of
anxiolytics – diazepam 50 mg/day and on the 11th day
since the start of the treatment he was prescribed haloperi-
dol, parenterally, at a total daily dose of 30 mg. As a reac-
tion to this therapy a sudden change in his mood occured
(he became negativistic and mutistic). A day after the an-
typsychotic therapy was administered, his body tempera-
ture elevated up to 38
oC, and some laboratory values in-
creased: creatine phosphokinase (CPK) – 1706 U/L (normal
values 26–200 U/L), leucocytes – 15,000 u10
9/L (normal
4,000–10,000  u10
9/L), ALT – 135 U/L (normal 10–49),
AST – 73 U/L (normal 0–37 U/L). As for the neurological
status rigidity and tremor were registered in all the ex-
tremities. As the differential diagnosis NMS and viral en-
cephalitis were considered. Antipsychotic therapy was im-
mediately stopped. Because of the suspected encephalitis
(headache, cough, febrility, altered state of consciousness),
computed tomography (CT) of the head and lumbar punc-
ture were performed. CT was normal. The lumbar puncture
showed 8 lymphocytes/mm
3 (normal values – lymphocytes
 5 mm
3). The serological tests of the CSF were normal.
Due to the poor somatic state the patient was transferred
(on the day 13) to the Clinic for Internal and Emergency
Medicine of the Military Medical Academy. On admission
he was conscious, disoriented, poorly communicative, hy-
pertensive (200/120 mmHg), febrile (38.6ºC), with rigidity
and tremor reported in his neurological status. The antibiotic
(ceftriaxone 2 g/day), antihypertensive and anticholinergic
(biperiden 10 mg/day) therapies were immediately started.
After the second lumbar puncture analysis of the cerebrospi-
nal fluid showed 5 elements/mm
3 (normal – lymphocytes
 5 mm
3), glucose 5.7 mmol/L (normal values 2.2–4.4
mmol/L); other findings from cerebrospinal fluid (CSF) (se-
rological analysis, proteins) were normal. On the day 14 after
the initiation of the treatment EEG reading indicated theta
dysfunction in the right frontocentral region.
Since the differential diagnosis ruled out viral encepha-
litis, on the day 15 from the start of the tretament the patient
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to the Clinic he was febrile (38.6ºC) and very agitated. The
blood values obtained by the repeated laboratory tests
showed the leucocyte count of 20,000 u 10
9/L, and the eryth-
rocyte sedimentation rate (SE) of 30 mm/1h (normal values
< 25 mm/1 h). His blood pressure was elevated (160/110
mmHg). The rigidity in muscles accompanied by the pro-
nounced tremor and excessive sweating was still present in
his neurological status. The slowness of movement and
speech, disorientation in time and space and confusion were
identified by psychiatric observation. In the course of his
treatment daily oscillations from somnolency to the state of
agitation with paranoid delusions were registered. At that
point the patient was treated only with symptomatic therapy
(intravenous rehydration polyvitamin, diazepam in high
doses – 50 mg/day, antibiotics – ceftriaxone 2 g/day, antihy-
pertensives).
On the day 22 after the start of the treatment the pa-
tient's laboratory values and blood pressure were normalized,
so his antihypertensive and antibiotics therapy was with-
drawn. The rigidity and tremor also disappeared and during
the examination of the muscle tone an active muscle resis-
tance was noted. With the improvement of his somatic con-
dition the clinical picture of confusion, delirium syndrome
was becoming more pronounced. Therefore, an atypical an-
typsychotic drug (clozapine 75 mg/day) and an affective sta-
bilizer (valproate 1500 mg/day) were introduced into his
therapy on the day 23 from the start of the treatment. Since
the above-described clinical picture persisted even after the
administered antipsychotic drug therapy, electroconvulsive
therapy (ECT) was added to his therapy on the day 28, with
the informed consent of the patient’s close relative. The
course of ECT consisted of 4 applications administered in
the 2 following weeks.
EEG was performed 3 times (on the days 14, 21 and 34)
and each time theta dysfunction was recorded in the right
frontal region. The patient also underwent magnetic reso-
nance imaging (MRI) of the head with contrast – the findings
were normal. One month after the beginning of the treatment
the patient was clinically stable, with no symptoms of confu-
sion, delirium syndrome, but with persistent paranoid delu-
sions. The therapy was not changed and on the day 48 the
fourth EEG was performed, which, in comparison to the pre-
vious findings, displayed the phase of recovery. The fifth
EEG, carried out at the completion of his hospital treatment
(on the day 75), was normal. Medical check-ups in an outpa-
tient setting (the first after 2 weeks and later repeatedly at
one-month intervals), showed that the patient was in stable
remission, with complete distancing from paranoid delu-
sions. He underwent antipsychotic drug therapy with cloza-
pine and an affective mood stabilizer (valproate) given at the
remission-maintaining doses of 50 mg and 1000 mg per day
respectively. Six months upon the completion of his hospital
treatment full recovery with normal clinical psychiatric and
neurological findings was recorded. The laboratory values of
biochemical and hematological values fell within the normal
ranges. The EEG readings were normal. As the patient’s
medical condition and recovery remained stable, the therapy
was withdrawn.
Discussion
NMS most often occurs during the first administration
of antipsychotic drug therapy, or after the increase in the
dose of antipsychotic. Risk factors associated with the devel-
opment of neuroleptic malignant syndrome range from the
ambient temperature rise, dehidration, agitation or catatonia,
the use of high-potency neuroleptic drugs or depot prepara-
tions, to an organic brain damage and the concomitant use of
lithium or anticholingerics.
To diagnose NMS it is necessary to take a thorough
medical history, perform somatic and neurological examina-
tion and monitor laboratory parameters 
12. For now, there are
no generally accepted diagnostic criteria for NMS, but the
most commonly used criteria are DSM IV 
13 and Levenson
criteria which require the existence of all the 3 major symp-
toms (fever (> 38
oC), rigidity, increased CPK), or 2 major
and 4 out of 7 minor symptoms (tachycardia, abnormal blood
pressure, tachypnea, leukocytosis (10,000–40,000 u 10
9/L),
altered consciousness, sweating) 
7, 14.
The presented patient developed a clinical picture of
NMS within 24 h after the administration of the typical anti-
psychotic, haloperidol, in the daily dose of 30 mg. Informa-
tion about the occurence of a strong headache and cough in
early stages of the disease required a detailed examination of
the patient, because the differential diagnose raised the ques-
tion whether NMS masked the primary CNS infectious dis-
ease 
3, 4, 14. For this reason and also because of the lympho-
cytic pleocytosis (8 limphocytes/mm
3 – on the day 10 from
the start of the treatment), the patient was thoroughly neuro-
logically and infectologically examined (lumbar puncture,
serological analysis CSF, CT, MRI, EEG).
EEG was performed on several occasions (on the days
14, 21, 34, 48 and 75). Theta dysfunction was registered in
the right frontocentral region, corresponding with the pe-
riod when confusiondelirium syndrome was most promi-
nent (on the days 14, 21 and 34). As the patient's clinical
findings improved, the EEG results improved as well (on
the day 48 and 75).
Such changes in EEG were also mentioned by other
authors who were describing NMS 
15. Very few studies so far
performed have established that it is most likely that dopa-
mine blockade leads to changes in neural pathways, causing
abnormal EEG 
16.
The diagnostic criteria for encephalitis
 10, 11 are: general
signs of inflammation, including changes on the skin, mu-
cous membrane and lymph nodes; neurological signs (hemi-
paresis, aphasia, ataxia, pyramidal signs deficits, autonomic
dysfunction, etc.); changes in laboratory blood tests (lym-
phocytosis is characteristic of viral encephalitis, while leuco-
penia and thrombocytopenia are characteristic of viral hem-
orrhagic fevers); changes in X-ray of the lungs; changes in
EEG readings, most often temporofrontally slow rhytm or
recurrent complex 
17; changes in CT or MRI of the head
(with contrast), such as hyperintensity, edemas, hemorrhage,
or inflamation; temporal lobe hyperperfusion registered on
Single Photon Emission Computed Tomography (SPECT);
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pleocytosis (> 5 lymphocytes/mm
3), glucose normal, proteins
normal/or slightly elevated. The results of > 5 lympho-
cytes/mm
3 are found in 95% of acute viral encephalitis cases;
serological analysis of CSF.
Table 1 shows that the patient met all the criteria for
NMS, while the evidence for acute viral encephalitis was a
suspicious CSF finding (borderline lymphocytes per mm
3),
as well as general signs at the biginning of the treatment
(headache, cough). The changes verified in EEG are de-
scribed in NMS, as well as in acute viral encephalitis 
10, 15, 16.
After an episode of NMS it is necessary to include anti-
psychotics into the therapy again, in order to control psychi-
atric symptoms. The scientific literature contains evidence
that rechallenging the patient with the same antipsychotic re-
sults in NMS recurring in 5 out of 6 cases. The use of lower
potency antipsychotics is safe in 9 out of 10 cases. The intro-
duction of atypical antipsychotic in a lower dose with regular
monitoring for symptoms of NMS is one of the safest meth-
ods of treatment 
2.
After the withdrawal of NMS symptoms (on the day 23
from the start of the treatment) the patient presented in this
case was given clozapine in small doses 
2, 18 and ECT was
performed, as well.
Electroconvulsive therapy can reduce hyperpyrexia,
perspiration, delirium, probably by modulating the dopamine
activity in the brain. First effects of ECT therapy are usually
registered after the fourth application of ECT 
14, which is ex-
actly the number of treatments the respective patient re-
ceived. The application of ECT should be particularly con-
sidered when it comes to patients who do not show any signs
of improvement even 48 h after the pharmacological treat-
ment, or when the clinical picture is not clear, i.e. when the
cause of the symptoms could be NMS, malignant catatonia,
or mood disorder 
14.
Conclusion
We presented the difficulties in early diagnosis at the
first episode of acute psychotic disorder associated with
acute febrile condition. For the differential diagnose it is
necessary to consider potentially fatal NMS and viral en-
cephalitis, i.e. neuroradiological diagnostics, cerebrospinal
fluid analysis and laboratory tests need to be done. In the
treatment of NMS, in addition to excluding the prescribed
antipsychotic and administration of a symptomatic therapy, a
combination of ECT and low doses of atypical antipsychotic
proved to be successful. Outpatient follow-up (6 months af-
ter the hospital treatment), alongside with monitoring of
laboratory parameters and follow-up EEG, showed a com-
plete recovery of the patient.
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